Abstract
The epidemic of HIV/AIDS is sweeping across the world. It is of great importance to figure out new ways to curb this disease. Epitope-based vaccine is one of these solutions. In this study, a chimeric gene was obtained by combination of a designed HIV-1 multi-epitope gene (MEG) and HIV-1 p24 gene. A recombinant plasmid pUTA2-MEGp24 was then constructed by inserting MEGp24 gene into the downstream of the promoter (ATI-P7.5×20) of fowlpox virus (FPV) transfer vector pUTA2. The recombinant plasmid and wild-type FPV 282E4 strain were then co-transfected into CEF cells and homologous recombination occurred. A recombinant virus expressing HIV-1 protein MEGp24 was screened by genome PCR and Western blot assay. Large scale preparation and purification of the recombinant fowlpox virus (rFPV) were then carried out. BALB/c mice were immunized intramuscularly with the rFPV for three times on day 0, 14 and 42. Mice were executed and sampled one week after the third inoculation. Anti-HIV-1 antibody in serum and Th1 cytokines in the supernatant of cultured spleen cells were assayed by ELISA. The count of T lymphocyte subsets and the CTL activity of spleen lymphocytes were analyzed by flow cytometry and lactate dehydrogenase (LDH) release assay, respectively. The results showed that HIV-1 specific antibody in serum and increased T lymphocyte subsets (CD4+ T, CD8+ T) were detected in the immunization group. CTL target-killing activity and higher secretion of Th1 cytokines (IFN-γ and IL-2) of spleen lymphocytes stimulated by H-2d-restricted CTL peptide were observed in immunized mice. We concluded that the rFPV may induce HIV-1 specific immunity especially cellular immunity in mice.
Similar content being viewed by others
References
Borrow P H, Lewicki B H, Hahn G M, et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol, 1994, 68: 6103–6110
Musey L J, Hughes T, Schacker T, et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med, 1997, 337: 1267–1274
Novitsky V, Smith U R, Gilbert P, et al. Human immunodeficiency virus type 1 subtype C molecular phylogeny: Consensus sequence for an AIDS vaccine design? J Virol, 2002, 76(11): 5435–5451
Williamson A L, Marais D, Passmore J A, et al., Human papilloma virus (HPV) infection in Southern Africa: Prevalence, immunity, and vaccine prospects. IUBMB Life, 2002, 53(4–5): 253–258
Mashishi T, Loubser S, Hide W, et al. Conserved domains of subtype C Nef from South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. AIDS Res Hum Retroviruses, 2001, 17(17): 1681–1687
Li Z J, Jin N Y, Jiang W Z, et al. A new type of multiple-epitope DNA vaccine against HIV. Chin J Microbiol Immunol (in Chinese), 2004, 24(11): 910–913
Wang H W, Jin N Y, Liu Z, et al. Preparation and identification of the anti-HIV-1 core protein monoclonal antibody. Chin J Cell Mol Immunol (in Chinese), 1998, 14(1): 63–64
Sambrook J, Russell D W. Molecular Cloning: A Laboratory Manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press, 2001. 1.31–1.162
Olive C, Toth I, Jackson D. Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies. Mini Rev Med Chem, 2001, 1: 429–438
Jackson D, Purcell A, Fitzmaurice C, et al. The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer. Curr Drug Targets, 2002, 3: 175–196
Sciutto E, Fragoso G, Manoutcharian K, et al. New approaches to improve a peptide vaccine against porcine Taenia solium cysticercosis. Arch Med Res, 2002, 33: 371–378
Gedvilaite A, Frommel C, Sasnauskas K, et al. Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polymavirus major capsid protein. Virology, 2000, 273: 21–35
Zhang L S, Jin N Y, Song Y J, et al. Immune responses of a designed HIV-1 DNA vaccine on rhesus monkeys. Chin Sci Bull, 2006, 51(13): 1571–1577
Butter C, Sturman T D, Baaten B J, et al. Protection from infectious bursal disease virus (IBDV)-induced immunosuppression by immunization with a fowlpox recombinant containing IBDV-VP2. Avian Pathol, 2003, 32(6): 597–604
Qiao C L, Yu K Z, Jiang Y P, et al. Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes. Avian Pathol, 2003, 32(1): 25–32
Karaca K, Sharma J M, Winslow B J, et al. Recombinant fowlpox viruses coexpressing chicken type I IFN and Newcastle disease virus HN and F genes: Influence of IFN on protective efficacy and humoral responses of chickens following in ovo-or post-hatch administration of recombinant viruses. Vaccine, 1998, 16(16): 1496–1503
Mehdy Elahi S, Bergeron J, Nagy E, et al. Induction of humoral and cellular immune responses in mice by a recombinant fowlpox virus expressing the E2 protein of bovine viral diarrhea virus. FEMS Microbiol Lett, 1999, 171(2): 107–114
Zhao H L, Jin N Y, Guo Z R, et al. Construction and identification of recombinant fowlpox virus expressing rabies virus glycoprotein. Chin J Vet Sci (in Chinese), 2004, 24(1): 37–39
Jin N Y, Zhang H Y, Yin G F, et al. Construction and immunogenecity of a recombinant fowlpox virus co-expressing FMDV P1-2A and 3Cpro gene. Chin Sci Bull, 2004, 49(6): 576–579
Anderson R J, Hannan C M, Gilbert S C, et al. Enhanced CD8+ T cell immune responses and protection elicited against plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J Immunol, 2004, 172(5): 3094–3100
Tsang K Y, Palena C, Yokokawa J, et al. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Clin Cancer Res, 2005, 11(4): 1597–1607
Hutchings C L, Gilbert S C, Hill A V, et al. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol, 2005, 175(1): 599–606
Pamungkas J, De Rose R, Iskandriati D, et al. Comparison of whole gene and whole virus scrambled antigen approaches for DNA prime and fowlpox virus boost HIV type 1 vaccine regimens in macaques. AIDS Res Hum Retroviruses, 2005, 21(4): 292–300
Parks R J, Krell P J, Derbyshire J B, et al. Studies of fowlpox virus recombination in the generation of recombinant vaccines. Virus Res, 1994, 32(3): 283–297
Borrow P, Lewicki H, Hahn H, et al. Virus-specific CD8+ cytotoxicity T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol, 1994, 68: 6103–6110
Lubaki N M, Shepherd M E, Brookmeyer R S, et al. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38−DR-phenotype: Comparison of statistical methods for measurement. J Acquir Immune Defic Syndr, 1999, 22(1): 19–30
Romagnani S. The Th1/Th2 paradigm. Immunol Today, 1997, 18(6): 263–267
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by the China “863” Program (Grant No. 2003AA219051)
Rights and permissions
About this article
Cite this article
Zhang, L., Jin, N., Song, Y. et al. Construction and characterization of a recombinant fowlpox virus containing HIV-1 multi-epitope-p24 chimeric gene in mice. SCI CHINA SER C 50, 212–220 (2007). https://doi.org/10.1007/s11427-007-0017-1
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11427-007-0017-1